Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The final results of a multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)

Date

08 Oct 2016

Session

Poster Display

Presenters

Hideaki Bando

Citation

Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371

Authors

H. Bando1, T. Doi2, K. Muro3, H. Yasui4, T. Nishina5, K. Yamaguchi6, S. Takahashi7, H. Hasegawa8, S. Nomura8, H. Kuno9, K. Shitara1, A. Sato8, A. Ohtsu1

Author affiliations

  • 1 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 3 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-0021 - Nagoya/JP
  • 4 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka/JP
  • 5 Department Of Gastrointestinal Medical Oncology, Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 6 Department Of Gastroenterological Chemotherapy, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 7 Department Of Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo/JP
  • 8 Office Of Clinical Research Support, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 9 Department Of Diagnostic Radiology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
More

Resources

Background

American phase I studies have reported that the recommended dose of TAS-102 (trifluridine/tipiracil) was 25 mg/m2 b.i.d., although this schedule did not provide clinically relevant improvements in a phase II study of advanced gastric cancer (AGC). However, a pivotal phase III study revealed that TAS-102 at 35 mg/m2 b.i.d. provided a clinically relevant improvement in overall survival among patients with metastatic colorectal cancer. Thus, we re-evaluated the efficacy, safety, and pharmacokinetic (PK) parameters of TAS-102 at 35 mg/m2 b.i.d. in patients with AGC. In an expanded cohort, we also evaluated the safety and PK parameters of a 40 mg/m2 b.i.d. schedule.

Methods

All patients had undergone one or two previous chemotherapy regimens that contained fluoropyrimidine, platinum agents, and taxanes or irinotecan. In this study, we assessed the investigator-determined and the independent central review's disease control rate (DCR), response rate, progression-free survival (PFS), overall survival (OS), safety profiles, and PK profiles.

Results

Twenty-nine patients were assessable after completing the 35 mg/m2 b.i.d. schedule. The investigator-determined DCR was 65.5% (95% confidence interval [CI], 45.7–82.1%) and the independent central review's DCR was 51.9% (n = 27, 95% CI, 31.9–71.3%). The median PFS and OS were 2.9 months (95% CI, 1.1–5.3 months) and 8.7 months (95% CI, 5.7–14.9 months), respectively. The grade 3/4 adverse events included neutropenia (69.0%), leukopenia (41.4%), anemia (20.7%), and anorexia (10.3%). No AGC-specific toxicities were detected. In the expanded cohort, the averages of PK parameters dose-dependently increased for 6 patients treated with the 40 mg/m2 b.i.d. dosage. Although slightly higher grade 3–4 neutropenia (83.3%) and leukopenia (66.7%) were observed, the investigator-determined DCR was 50.0% (SD: 3; PD: 3) and no partial response cases were observed.

Conclusions

The 35 mg/m2 b.i.d. dose of TAS-102 provided positive efficacy and an acceptable toxicity profile in patients with AGC. A randomized, double-blind, placebo-controlled, phase III study is ongoing to validate these findings.

Clinical trial identification

UMIN000007421

Legal entity responsible for the study

Exploratory Oncology Research & Clinical Trial Center, National Cancer Center

Funding

The Renovation Project of Early and Exploratory Clinical Trial Center, National Cancer Center Research and Development Fund (24-A-1)

Disclosure

K. Muro, T. Nishina, A. Ohtsu: Honoraria: Taiho Pharmaceutical Company. S. Takahashi: Research funding: Taiho Pharmaceutical Company. S. Nomura: Japan Breast Cancer Research Group (JBCRG). Grants: Japan Agency for Medical Research and Development (AMED). A. Sato: Corporate-sponsored Research: Taiho, Boehringer-Ingelheim, Novartis, Bayer. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings